Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 1, 2006, Pages 13-23

  Horton, Terzah M ^a   Gannavarapu, Anurhadha ^a   Blaney, Susan M ^a   D'Argenio, David Z ^b   Plon, Sharon E ^a   Berg, Stacey L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Southern California ^*  (United States)

Author keywords

ALL; AML; PS 341; Synergy; VELCADE

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; ASPARAGINASE; BORTEZOMIB; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLAVOPIRIDOL; GELDANAMYCIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; MELPHALAN; PROTEASOME INHIBITOR; TETRAZOLIUM; TRICHOSTATIN A; VINCRISTINE; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; COLORIMETRY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; LEUKEMIA RELAPSE; LYMPHOBLAST; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; HEAT-SHOCK PROTEINS; HISTONE DEACETYLASES; HUMANS; INFANT; INHIBITORY CONCENTRATION 50; LEUKEMIA; MALE; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; TUMOR CELLS, CULTURED;

EID: 33646003521     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0135-z     Document Type: Article

References (57)

1. SEER Cancer Statistic Review, 1973-1999 Bethesda, MD: National Cancer Institute, 2000;467-482
2. Hochstrasser M (1995) Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 7:215-223
3. Spataro V, Norbury C, Harris AL (1998) The ubiquitin-proteasome pathway in cancer. Br J Cancer 77:448-455
4. Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79:13-21
5. Karin M, Cao Y, Greten FR et al (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301-310
6. Hideshima T, Chauhan D, Richardson P et al (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639-16647
7. Shinohara K, Tomioka M, Nakano H et al (1996) Apoptosis induction resulting from proteasome inhibition. Biochem J 317(Pt 2):385-388
8. Drexler HC (1997) Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad.Sci USA 94:855-860
9. Adams J, Palombella VJ, Sausville EA et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622
10. Papandreou CN, Daliani DD, Nix D et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121
11. Orlowski RZ, Stinchcombe TE, Mitchell BS et al (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427
12. Masdehors P, Merle-Beral H, Magdelenat H et al (2000) Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk Lymphoma 38:499-504
13. Hideshima T, Richardson P, Chauhan D et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076
14. Soligo D, Servida F, Delia D et al (2001) The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 113:126-135
15. Mitsiades N, Mitsiades CS, Richardson PG et al (2002) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377-2380
16. Pajonk F, Pajonk K, McBride WH (2000) Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 47:1025-1032
17. Dai Y, Rahmani M, Grant S (2003) Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK-and NF-kappaB-dependent process. Oncogene 22:7108-7122
18. Dai Y, Rahmani M, Pei XY et al (2004) Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 104:509-518
19. Mitsiades CS, Mitsiades NS, McMullan CJ et al (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101:540-545
20. Adachi M, Zhang Y, Zhao X et al (2004) Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin Cancer Res 10:3853-3862
21. Pei XY, Dai Y, Grant S (2003) The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 17:2036-2045
22. Wang CY, Mayo MW, Korneluk RG et al (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680-1683
23. Wang CY, Cusack JC Jr, Liu R et al (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nature Medicine 5:412-417
24. Izban KF, Ergin M, Huang Q et al (2001) Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod.Pathol 14:297-310
25. Richardson PG, Hideshima T, Mitsiades C et al (2004) Proteasome inhibition in hematologic malignancies. Ann Med 36:304-314
26. Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498
27. O'Connor OA, Wright J, Moskowitz C et al (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684
28. Goy A, Younes A, McLaughlin P et al (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675
29. An WG, Hwang SG, Trepel JB et al (2000) Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14:1276-1283
30. Yu C, Rahmani M, Dent P et al (2004) The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 295:555-566
31. Tan C, Waldmann TA (2002) Proteasome inhibitor PS-341, a potential therapeutic agent for adult T- cell leukemia. Cancer Res 62:1083-1086
32. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
33. Carmichael J, DeGraff WG, Gazdar AF et al (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936-942
34. Greco WR, Park HS, Rustum YM (1990) Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res 50:5318-5327
35. DiArgenio DZ, Schumitsky A (1997)ADAPT II Users guide: pharmacokinetic/pharmacodynamic systems analysis software. (4). Los Angeles, CA, Biomedical systems resource
36. Chou T, Talalay C (1984) Quantitative analysis of dose effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
37. Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617
38. Appleman LJ, Ryan DP, Clark JW, Eder JP, Fishman M, Cusack JC Jr, Fidias P, Supko JG, Guerciolini R, Esseltine D, Kashala O (2003) Phase I dose escalation study of bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors. Proc ASCO 22:A839
39. Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29(Suppl 1):21-31
40. Gatto S, Scappini B, Pham L et al (2003) The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in B positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88:853-863
41. Yu C, Rahmani M, Conrad D et al (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to ST1571. Blood 102:3765-3774
42. An J, Sun Y, Fisher M et al (2004) Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 18:1699-1704
43. Zheng B, Georgakis GV, Li Y et al (2004) Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 10:3207-3215
44. Chauhan D, Li G, Auclair D et al (2004) 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis 9:149-155
45. Brown RE, Bostrom B, Zhang PL (2004) Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann.Clin Lab Sci 34:203-205
46. Webb JL (1963) effect of more than one inhibitor. Enzymes and metabolic inhibitors ed Vol 1; New York: Academic Press, 66-79-487-512
47. Faessel HM, Slocum HK, Jackson RC et al (1998) Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation. Cancer Res 58:3036-3050
48. Chou JH (1991) Quantitation of synergism and antagonism of two or more drugs by computerized analysis. Synergism and antagonism in chemotherapy pp 223-241
49. Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezmib and histone deacetylase inhibitors. Clin Cancer Res 10:3839-3852
50. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47:331-385
51. Berenbaum MC (1989) What is synergy? Pharmacol Rev 41:93-141
52. Zoli W, Ricotti L, Tesei A et al (2001) In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 37:69-82
53. Chang TT, Chou TC (2000) Rational approach to the clinical protocol design for drug combinations: a review. Acta Paediatr Taiwan 41:294-302
54. Bonvini P, Dalla RH, Vignes N et al (2004) Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res 64:3256-3264
55. Richardson PG, Hideshima T, Mitsiades C et al (2004) Proteasome inhibition in hematologic malignancies. Ann Med 36:304-314
56. Blaney SM, Bernstein M, Neville K et al (2004) Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 22:4752-4757
57. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55